Atwood & Palmer Inc. Sells 3,400 Shares of Pfizer Inc. (NYSE:PFE)

Atwood & Palmer Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,539 shares of the biopharmaceutical company’s stock after selling 3,400 shares during the quarter. Atwood & Palmer Inc.’s holdings in Pfizer were worth $267,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the 4th quarter valued at approximately $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in shares of Pfizer during the 4th quarter valued at approximately $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PFE. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Price Performance

Shares of PFE stock opened at $23.97 on Tuesday. The stock has a 50 day moving average price of $22.93 and a 200 day moving average price of $24.98. The firm has a market capitalization of $136.26 billion, a P/E ratio of 17.00, a P/E/G ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.